1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

23 May 2024
Admin
News Article

Teva and Alvotech Introduce Simlandi Injection in US Markets

Overview

Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd. and Alvotech announced the availability of Simlandi (adalimumab-ryvk) injection in the US, as an interchangeable biosimilar to Humira for the treatment of adult rheumatoid arthritis, juvenile idiopathic arthritis, adult psoriatic arthritis, adult ankylosing spondylitis, Crohn’s disease, adult ulcerative colitis, adult plaque psoriasis, adult hidradenitis suppurativa and adult uveitis.

Teva on Biosimialrs

“We are proud to make Simlandi available in the US to patients and providers,” said Thomas Rainey, senior vice president, US market Access at Teva.
“Biosimilars create opportunities for cost savings across the healthcare system, and Simlandi’s launch now offers the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the US market. We will be working with payors to ensure access to Simlandi, as well as the six other biosimilars we are committed to bringing to market by 2027.”

Simlandi: FDA Approval

Simlandi is approved by the US Food and Drug Administration (FDA) as the first high-concentration, citrate-free biosimilar to Humira with interchangeability exclusivity for the 40mg/0.4mL injection.
While both low-concentration and high-concentration strength biosimilars of Humira are marketed in the US today, nearly 88 per cent of US prescriptions for adalimumab are for the high-concentration presentation.

Words from CCO: Alvotech

“It is a great pleasure to be able to offer US patients access to Simlandi, the only citrate-free, high-concentration interchangeable biosimilar to Humira. We look forward to increasing the availability of cost-effective quality biosimilars in the US, as they can be an important contributor to reduced inflationary pressure for healthcare providers and patients,” said Anil Okay, chief commercial officer of Alvotech.

About Partnership

Teva and Alvotech entered into a strategic partnership for the exclusive commercialization of five of Alvotech’s biosimilar product candidates in August 2020, and in July 2023, the collaboration was extended to include two additional biosimilars and new presentations of two previously partnered products.
Alvotech handles development and manufacturing, while Teva is responsible for the exclusive commercialization in the US, which leverages Teva’s experience and extensive sales and marketing infrastructure.
Simlandi is the first biosimilar launched under the strategic partnership, and in April 2024, the FDA approved Selarsdi (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and paediatric patients 6 years and older.

Humira is a registered trademark of AbbVie Biotechnology Ltd. Stelara is a registered trademark of Johnson & Johnson.

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine.

About Alvotech

Alvotech is a biotech company, founded by Robert Wessman, focused solely on the development and manufacture of biosimilar medicines for patients worldwide.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!